US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ORUKA THERAPEUTICS INC

14.25

+0.02000.14%

Post-market: 14.250.00000.00%17:20 EDT

Volume:70.22K

Turnover:992.53K

Market Cap:533.53M

PE:-4.68

High:14.35

Open:14.25

Low:13.70

Close:14.23

Loading ...

Overview Company News Filings

Oruka Therapeutics (ORKA) Receives a Buy from Stifel Nicolaus

Oruka Therapeutics Secures FDA Clearance for Phase 2a Trial of ORKA-001 in Psoriasis

MT Newswires Live

BRIEF-Oruka Therapeutics Announces Ind Clearance For Everlast-A Phase 2A Trial Of Orka-001 In Psoriasis With Phase 1 Data To Be Presented At Eadv In September

Oruka Therapeutics Announces Ind Clearance for Everlast-a Phase 2a Trial of Orka-001 in Psoriasis With Phase 1 Data to Be Presented at Eadv in September

THOMSON REUTERS

Oruka Therapeutics: Ind Cleared for Everlast-a Phase 2a Trial of Orka-001 in Moderate-to-Severe Psoriasis, With Initial Data Expected 2H 2026

THOMSON REUTERS

Oruka Therapeutics Promotes Laura Sandler to Chief Operating Officer Amidst Strategic Focus on Psoriatic Disease Treatment

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

THOMSON REUTERS

Oruka Therapeutics Inc. Conducted Annual Stockholders Meeting

Oruka Therapeutics (ORKA) Gets a Buy from BTIG

BTIG Initiates Oruka Therapeutics at Buy With $44 Price Target

MT Newswires Live

Oruka Therapeutics to Present at Jefferies Global Healthcare Conference in New York

Oruka Therapeutics Begins Dosing in Phase 1 Trial of ORKA-002 for Skin Disease Treatment

MT Newswires Live

Oruka Therapeutics Inc: on Track to Initiate a Phase 2 Study in 1H 2026

THOMSON REUTERS

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of Orka-002, Its Novel Half-Life Extended Anti-Il-17a/F Antibody

THOMSON REUTERS

Oruka Therapeutics Initiates Phase 1 Trial of Novel Anti-IL-17A/F Antibody ORKA-002, Aiming to Revolutionize Psoriasis Treatment

Oruka Therapeutics Price Target Maintained With a $40.00/Share by Wedbush

TD Cowen Remains a Buy on Oruka Therapeutics (ORKA)

Oruka Therapeutics Reports Q1 2025 Results: $20.9M Net Cash Used in Operations; Strong $373M Cash Position

Oruka Therapeutics Inc: Expects to Share Efficacy and Response Duration Data From This Study in 2H 2026

THOMSON REUTERS

Oruka Therapeutics: Strong Cash Position of $373 Mln Provides Runway Through 2027, Over One Year Past Anticipated Orka-001 Phase 2a Data in Psoriasis

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORKA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORKA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","market":"US","secType":"STK","nameCN":"ORUKA THERAPEUTICS INC","latestPrice":14.25,"timestamp":1753473600000,"preClose":14.23,"halted":0,"volume":70222,"hourTrading":{"tag":"盘后","latestPrice":14.25,"preClose":14.25,"latestTime":"17:20 EDT","volume":1380,"amount":19664.78,"timestamp":1753478441021},"delay":0,"floatShares":22419875,"shares":37440510,"eps":-3.042528,"marketStatus":"Market Closed","change":0.02,"latestTime":"07-25 16:00:00 EDT","open":14.25,"high":14.35,"low":13.7,"amount":992534.671502,"amplitude":0.045678,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.042528,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"listingDate":871012800000,"exchange":"NASDAQ","adjPreClose":14.23,"postHourTrading":{"tag":"盘后","latestPrice":14.25,"preClose":14.25,"latestTime":"17:20 EDT","volume":1380,"amount":19664.78,"timestamp":1753478441021},"volumeRatio":0.38203084608578103,"impliedVol":0.5249,"impliedVolPercentile":0.3462},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","floatShares":22419875,"roa":"--","roe":"--","lyrEps":-3.873702,"volumeRatio":0.38203084608578103,"shares":37440510,"dividePrice":0,"high":14.35,"amplitude":0.045678,"preClose":14.23,"low":13.7,"week52Low":5.485,"pbRate":"1.47","week52High":52.32,"institutionHeld":0.908,"latestPrice":14.25,"eps":-3.042528,"divideRate":0,"volume":70222,"delay":0,"ttmEps":-3.042528,"open":14.25,"prevYearClose":19.39,"prevWeekClose":14.54,"prevMonthClose":11.21,"prevQuarterClose":11.21,"fiveDayClose":14.54,"twentyDayClose":11.63,"sixtyDayClose":10.45},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORKA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553408223","title":"Oruka Therapeutics (ORKA) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2553408223","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553408223?lang=en_us&edition=fundamental","pubTime":"2025-07-21 23:17","pubTimestamp":1753111068,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus reiterated a Buy rating on Oruka Therapeutics, with a price target of $47.00. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-receives-a-buy-from-stifel-nicolaus-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-receives-a-buy-from-stifel-nicolaus-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","SF","BK4139","CFA","BK4127"],"gpt_icon":0},{"id":"2553479644","title":"Oruka Therapeutics Secures FDA Clearance for Phase 2a Trial of ORKA-001 in Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2553479644","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553479644?lang=en_us&edition=fundamental","pubTime":"2025-07-21 19:32","pubTimestamp":1753097542,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics  said Monday the US Food and Drug Administration has cleared its investigational new drug application to start the phase 2a trial of ORKA-001 intended for moderate to severe psoriasis.The company said it aims to enroll about 80 patients under the trial, with a primary endpoint of PASI 100 or completely clear skin.Oruka Therapeutics said it expects to release efficacy and response duration data from the phase 2a trial in H2 2026.Shares of Oruka Therapeutics were up more than 7% in recent premarket activity Monday.Price: 15.60, Change: +1.06, Percent Change: +7.29","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2553476133","title":"BRIEF-Oruka Therapeutics Announces Ind Clearance For Everlast-A Phase 2A Trial Of Orka-001 In Psoriasis With Phase 1 Data To Be Presented At Eadv In September","url":"https://stock-news.laohu8.com/highlight/detail?id=2553476133","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553476133?lang=en_us&edition=fundamental","pubTime":"2025-07-21 19:02","pubTimestamp":1753095757,"startTime":"0","endTime":"0","summary":"BRIEF-Oruka Therapeutics Announces Ind Clearance For Everlast-A Phase 2A Trial Of Orka-001 In Psoriasis With Phase 1 Data To Be Presented At Eadv In SeptemberJuly 21 (Reuters) - Oruka Therapeutics Inc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nTUA8KMLNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2553476300","title":"Oruka Therapeutics Announces Ind Clearance for Everlast-a Phase 2a Trial of Orka-001 in Psoriasis With Phase 1 Data to Be Presented at Eadv in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2553476300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553476300?lang=en_us&edition=fundamental","pubTime":"2025-07-21 19:00","pubTimestamp":1753095601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nTUA8KMLNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2553047666","title":"Oruka Therapeutics: Ind Cleared for Everlast-a Phase 2a Trial of Orka-001 in Moderate-to-Severe Psoriasis, With Initial Data Expected 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2553047666","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553047666?lang=en_us&edition=fundamental","pubTime":"2025-07-21 19:00","pubTimestamp":1753095601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nTUA8KMLNY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2548688262","title":"Oruka Therapeutics Promotes Laura Sandler to Chief Operating Officer Amidst Strategic Focus on Psoriatic Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2548688262","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548688262?lang=en_us&edition=fundamental","pubTime":"2025-07-02 04:01","pubTimestamp":1751400071,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics, Inc., a biotechnology company focused on treatments for chronic skin diseases, has announced the promotion of Laura Sandler to Chief Operating Officer. Sandler, who joined Oruka in 2024 as SVP of Operations, has extensive experience in biopharmaceutical leadership and has been instrumental in advancing the company's clinical programs. Prior to Oruka, she held senior roles at CRISPR Therapeutics, MedImmune, Quintiles, Novartis, and bluebird bio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on July 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL9tzKHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN.UK","ORKA","NDAQ"],"gpt_icon":0},{"id":"2548882613","title":"Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2548882613","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548882613?lang=en_us&edition=fundamental","pubTime":"2025-07-02 04:01","pubTimestamp":1751400060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nTUABNCDWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2540045497","title":"Oruka Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540045497","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540045497?lang=en_us&edition=fundamental","pubTime":"2025-06-04 04:00","pubTimestamp":1748980849,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL36JrD0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2540767180","title":"Oruka Therapeutics (ORKA) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2540767180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540767180?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:16","pubTimestamp":1748862982,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA – Research Report) received a Buy rating and a $44.00 price target from BTIG analyst Julian Harrison today. According to T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-btig-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2537943179","title":"BTIG Initiates Oruka Therapeutics at Buy With $44 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2537943179","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537943179?lang=en_us&edition=fundamental","pubTime":"2025-05-22 19:33","pubTimestamp":1747913599,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) has an average rating of buy and mean price target of $39.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","ORKA"],"gpt_icon":0},{"id":"2537328982","title":"Oruka Therapeutics to Present at Jefferies Global Healthcare Conference in New York","url":"https://stock-news.laohu8.com/highlight/detail?id=2537328982","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537328982?lang=en_us&edition=fundamental","pubTime":"2025-05-21 19:00","pubTimestamp":1747825224,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc., a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases, will be presenting at the Jefferies Global Healthcare Conference in New York on June 4th, 2025. The presentation will highlight Oruka's advancements in treatments for conditions such as plaque psoriasis. A webcast and replay will be accessible through the Oruka investor events website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDLpf2R8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4112","IE00BGHQF748.EUR","BK4139","ORKA","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","NDAQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2537626418","title":"Oruka Therapeutics Begins Dosing in Phase 1 Trial of ORKA-002 for Skin Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2537626418","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537626418?lang=en_us&edition=fundamental","pubTime":"2025-05-21 05:46","pubTimestamp":1747777610,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics  said late Tuesday it has commenced dosing healthy volunteers in its phase 1 trial for ORKA-002, a novel, long-acting monoclonal antibody designed to target IL-17A/F for the treatment of chronic skin diseases.The trial will assess the safety, tolerability, and pharmacokinetics of three subcutaneous dose levels in about 24 participants, the biotechnology company said, adding that preclinical data indicates that ORKA-002 may allow dosing just two to three times annually for psoriasis patients, representing a notable advancement over the current standard of care.The company said it expects releasing interim data by the end of 2025 and aims to begin a phase 2 trial for moderate-to-severe psoriasis in the first half of 2026. The planned phase 2 study will evaluate various dose levels, with the primary endpoint being PASI 100 at week 16.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2537623776","title":"Oruka Therapeutics Inc: on Track to Initiate a Phase 2 Study in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2537623776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537623776?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:33","pubTimestamp":1747773229,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nFWN3RS24D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2537623774","title":"Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of Orka-002, Its Novel Half-Life Extended Anti-Il-17a/F Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2537623774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537623774?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:33","pubTimestamp":1747773229,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nFWN3RS24D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2537628230","title":"Oruka Therapeutics Initiates Phase 1 Trial of Novel Anti-IL-17A/F Antibody ORKA-002, Aiming to Revolutionize Psoriasis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2537628230","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537628230?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:01","pubTimestamp":1747771272,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Initiates Phase 1 Trial of Novel Anti-IL-17A/F Antibody ORKA-002, Aiming to Revolutionize Psoriasis Treatment. Oruka Therapeutics, Inc., a biotechnology company specializing in novel biologics for chronic skin diseases, has announced the commencement of its first clinical trial for ORKA-002. This trial involves dosing healthy volunteers with ORKA-002, a half-life extended monoclonal antibody targeting IL-17A/F, which is administered subcutaneously. The Phase 1 trial is designed as a double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 across three subcutaneous dose cohorts in approximately 24 participants. Interim data from this study is expected by the end of 2025. Oruka aims to initiate a Phase 2 study of ORKA-002 in moderate-to-severe psoriasis in the first half of 2026, with a focus on assessing multiple dose levels and regimens.Disclaimer: This news brief was created by Public Technologies  using generativ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDLFnX7p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","ORKA","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","BK4585","BK4588","NDAQ"],"gpt_icon":0},{"id":"2535827927","title":"Oruka Therapeutics Price Target Maintained With a $40.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2535827927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535827927?lang=en_us&edition=fundamental","pubTime":"2025-05-15 23:04","pubTimestamp":1747321440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORKA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 11:04 ET (15:04 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","LENZ"],"gpt_icon":0},{"id":"2535887554","title":"TD Cowen Remains a Buy on Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535887554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535887554?lang=en_us&edition=fundamental","pubTime":"2025-05-15 07:56","pubTimestamp":1747266990,"startTime":"0","endTime":"0","summary":"In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report). The company’s sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-oruka-therapeutics-orka?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-oruka-therapeutics-orka?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","BK4585","BK4566","BK4207","BK4127","ORKA","COWN","BK4139"],"gpt_icon":0},{"id":"2535007212","title":"Oruka Therapeutics Reports Q1 2025 Results: $20.9M Net Cash Used in Operations; Strong $373M Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007212","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007212?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:21","pubTimestamp":1747254062,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL9YJMMl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","LU2210150020.SGD","ORKA","BK4112","NDAQ","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4585"],"gpt_icon":0},{"id":"2535071300","title":"Oruka Therapeutics Inc: Expects to Share Efficacy and Response Duration Data From This Study in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2535071300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535071300?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:15","pubTimestamp":1747253701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA18LQC2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2535007132","title":"Oruka Therapeutics: Strong Cash Position of $373 Mln Provides Runway Through 2027, Over One Year Past Anticipated Orka-001 Phase 2a Data in Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007132?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:15","pubTimestamp":1747253701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA18LQC2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORKA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-03","symbol":"ORKA","defaultRemindTime":1725370200000,"type":"split","dateTimestamp":1725336000000,"forFactor":12,"toFactor":1,"ratio":12},{"date":"2024-08-29","symbol":"ORKA","amount":1.613,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-26","defaultRemindTime":1724938200000,"name":"方舟生物医药","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-28","payableDate":"2024-08-26","currency":"USD","dateTimestamp":1724904000000,"payDate":"2024-08-28"},{"market":"US","date":"2024-08-01","symbol":"ORKA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722484800000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-04-25","symbol":"ORKA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2024-02-01","symbol":"ORKA","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"post","actualEps":-0.08}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORKA\",market:\"US\",,,undefined,":[{"executeDate":"2024-08-29","recordDate":"2024-08-26","paymentDate":"2024-08-28","value":1.613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORKA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":9,"updateTime":1747972800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ORKA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ORKA","date":"2025-07-25","current":-5.061679,"percent":0.084211,"low":-5.463625,"twenty":-4.767415,"median":-4.21456,"eighty":-3.877182,"high":-2.779284,"avg":-4.262288,"sd":0.566214,"marketCap":532778457},"quantilePoints":[{"date":"2025-03-14","current":-4.566552,"twenty":-4.600166,"median":-4.533759,"eighty":-4.155287,"marketCap":417087281},{"date":"2025-03-21","current":-4.898591,"twenty":-4.788731,"median":-4.634189,"eighty":-4.465422,"marketCap":447414094},{"date":"2025-03-28","current":-4.898591,"twenty":-4.90187,"median":-4.734621,"eighty":-4.543597,"marketCap":447414094},{"date":"2025-04-04","current":-3.656521,"twenty":-4.90187,"median":-4.68543,"eighty":-4.155287,"marketCap":333969349},{"date":"2025-04-11","current":-3.021139,"twenty":-4.898591,"median":-4.546056,"eighty":-3.567158,"marketCap":275936558},{"date":"2025-04-17","current":-3.529445,"twenty":-4.883833,"median":-4.205819,"eighty":-3.28595,"marketCap":322362791},{"date":"2025-04-25","current":-4.304201,"twenty":-4.810047,"median":-4.25501,"eighty":-3.440082,"marketCap":393125355},{"date":"2025-05-02","current":-4.136132,"twenty":-4.747739,"median":-4.214018,"eighty":-3.521247,"marketCap":377774745},{"date":"2025-05-09","current":-3.996758,"twenty":-4.714945,"median":-4.198946,"eighty":-3.605691,"marketCap":365044972},{"date":"2025-05-16","current":-3.364967,"twenty":-4.682151,"median":-4.136132,"eighty":-3.605691,"marketCap":354187224},{"date":"2025-05-23","current":-3.980336,"twenty":-4.607544,"median":-4.002451,"eighty":-3.625269,"marketCap":418959306},{"date":"2025-05-30","current":-4.215101,"twenty":-4.558354,"median":-4.038702,"eighty":-3.660839,"marketCap":443670043},{"date":"2025-06-06","current":-4.336041,"twenty":-4.541137,"median":-4.079934,"eighty":-3.705732,"marketCap":456399816},{"date":"2025-06-13","current":-4.57792,"twenty":-4.558354,"median":-4.136132,"eighty":-3.769048,"marketCap":481859363},{"date":"2025-06-20","current":-4.261343,"twenty":-4.543597,"median":-4.170639,"eighty":-3.777968,"marketCap":448537309},{"date":"2025-06-27","current":-4.136846,"twenty":-4.523383,"median":-4.154632,"eighty":-3.785238,"marketCap":435433131},{"date":"2025-07-03","current":-4.48188,"twenty":-4.48188,"median":-4.154632,"eighty":-3.808193,"marketCap":471750426},{"date":"2025-07-11","current":-5.004766,"twenty":-4.566552,"median":-4.184867,"eighty":-3.812292,"marketCap":526787975},{"date":"2025-07-18","current":-5.463625,"twenty":-4.701827,"median":-4.197316,"eighty":-3.861483,"marketCap":575086233},{"date":"2025-07-25","current":-5.061679,"twenty":-4.767415,"median":-4.21456,"eighty":-3.877182,"marketCap":532778457}],"updateTime":1753575768737}}}